ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Estimating Risk of Guillain-Barré Syndrome in US Medicare-enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease: A Self-controlled Case Series Analysis.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A narrative review of considerations when assessing potential relationships between Guillain-Barré syndrome and vaccines.Human vaccines & immunotherapeutics · 2026Review
- Increasing Incidence of Guillain-Barré Syndrome in the USA among Integrated Delivery Systems from 2017 to 2023: Trends by Age and Charlson Comorbidity Index Score.Neuroepidemiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundGuillain-Barré syndrome (GBS) is considered a rare complication of viral respiratory infections (eg, influenza, severe acute respiratory syndrome coronavirus 2); however, its association with respiratory syncytial virus (RSV) infection has not been studied. We performed a self-controlled case series analysis to estimate GBS risk following medically attended RSV disease among older adults.
methodsWe identified adults aged ≥65 years with medically attended RSV disease and incident inpatient GBS using specific International Classification of Diseases (ICD) codes, excluding those with prior GBS, from the US Medicare claims data (2011-2024). Risk period was 1 to 42 days after the RSV disease index date; the control period encompassed -180 to -22 days and 43 to 180 days of RSV disease index date. Conditional Poisson regression estimated RSV-related GBS incidence rate ratios (IRRs), adjusting for seasonality and viral activities. Medicare data policies prohibit cell case counts <11 from being displayed.
resultsAmong 452 471 eligible patients with RSV disease, <11 incident GBS cases occurred in the risk period and 34 during the control period. The adjusted IRR for GBS after RSV disease was 2.11 (95% confidence interval, 1.01-4.37), consistent across sensitivity analyses of alternative risk/control periods and after excluding coinfections. The IRR increased to 2.59 (1.17-5.73) after ICD-10 code adoption, with a marked rise among patients aged ≥75 years (3.98 [1.45-10.91]).
conclusionsGBS risk increases after RSV disease compared to control periods not temporally adjacent to RSV disease, with an effect particularly evident among patients aged ≥75 years. RSV should be recognized as 1 of the pathogens that may rarely lead to GBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.